Document is current

Article History

Received: 25 January 2024

Accepted: 25 October 2024

First Online: 27 December 2024

Declarations

:

: Ethics approval was conferred by the Research and Ethics Committee in Lesotho (Ref: ID 2021-29) on 13 June 2021 and a waiver conferred by the Ministry of the Health and Social Services, Research Management Committee off ice of the Executive Director in Namibia (Ref: 17/3/3/SJ) on 12 May 2021. Ethics approval was not applicable in the other country assessments as the ministries of health led and deemed them programme assessments. The information collected during the desk review is public available data and the key informants all participated within their official capacity and were selected by the ministries of health. Verbal informed consent to participate in the assessment was obtained from all participants.

: Consent was sought from the Research Management Committee (RMC) of the Ministry of Health and Social Services (MoHSS) in Namibia, as requested in the approval for publication of the report: Landscape assessment on availability of Co-package mifepristone-misoprostol (Combipack) letter from the MoHSS, to publish the manuscript in a peer review journal. No other consent was needed.

: The views expressed in this article are those of the authors and do not necessarily represent the views of, and should not be attributed to, the World Health Organization. The mention of specific companies or of certain manufacturers’ products does not imply that they are endorsed or recommended by WHO in preference to others of a similar nature that are not mentioned. Errors and omissions excepted the names of proprietary products are distinguished by initial capital letters.

: The authors declare that they have no competing interests.